Mylan Pharmaceuticals Pvt Ltd has extended its portfolio by launching eight women’s care products.
The initial offering focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome.
Mylan CEO Heather Bresch commented: “The launch of Mylan’s Women’s Care portfolio expands and strengthens our growing commercial platform in India.”
The company’s President Rajiv Malik said: “We expect to continue to expand into new therapeutic categories, further expand our field force and leverage our distribution capabilities in India.”
Mylan Pharmaceuticals, with a manufacturing base in Hyderabad, is a subsidiary of US-based Mylan Inc. It is engaged in manufacturing a comprehensive range of antiretroviral products. Mylan Inc, a leading generic and specialty pharmaceutical company, had acquired Indian company Matrix Laboratories in 2007. Mylan has a portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. It also produces a range of anti-retroviral therapies, upon which approximately 40 per cent of HIV/AIDS patients in developing countries depend, the company said in a press release.